Short answer
Outset Medical, Inc. (OM) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $34M (up 14.2% year over year) with net income of −$15M.
Q3 2026 key financials · XBRL
- Revenue
- $34M
- +14.2% YoY · +6.2% QoQ
- Net income
- −$15M
- +17.7% YoY · +18.3% QoQ
- Operating margin
- -36.5%
- Gross margin
- 40.7%
- EPS (diluted)
- −$0.78
- +2.5% YoY · +19.6% QoQ
Source: XBRL data from the Outset Medical, Inc. (OM) Q3 2026 10-Q on SEC EDGAR. USD.
Outset Medical, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $33.6M, up 14% YoY from $29.4M, driven by product revenue up 15% to $23.7M
- Gross margin 40.7% vs 39.4% YoY, with service and other revenue up 12% to $9.9M
- Operating loss $12.3M vs $15.8M YoY, net loss $14.7M vs $17.8M
- Cash, restricted cash and short-term investments $140.7M; nine-month operating cash outflow $32.9M
- Near-term losses expected; customer purchase deferrals, tariffs, policy uncertainty and cautious capital spending remain headwinds
Risk Factors
- New FDA Form 483 triggered by Q3 2026 San Jose inspection, citing CAPA, complaint handling, change documentation and data analysis
- Regulatory compliance risk: unresolved FDA observations could bring further communications or official action
- Operational risk: supplier noncompliance could disrupt timely production and required product quantities
- Product risk: unanticipated adverse events could trigger labeling changes, restrictions or recalls
- Financial risk: continued FDA remediation costs and management time may be significant
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Outset Medical, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.